ArticleBioinformation2025
Research landscape of precision medicine in cardiology.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular innovation without equity risks widening global gaps.MedScience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine in cardiology integrates genomic, proteomic, and phenotypic data to tailor prevention, diagnosis, and treatment strategies for individual patients. Recent advances have identified genetic variants associated with arrhythmias, cardiomyopathies, and coronary artery disease, enabling risk stratification and targeted therapies. High-throughput "omics" technologies and machine-learning algorithms have facilitated the discovery of novel biomarkers and have refined phenotypic subgroups within heterogeneous cardiac disorders. Pharmacogenomic profiling has demonstrated potential to optimize drug selection and dosing, reducing adverse events and improving therapeutic efficacy. Despite these breakthroughs, challenges such as data integration, clinical implementation barriers, and ethical considerations remain. Ongoing efforts in large-scale consortia, real-world data registries, and adaptive clinical trial designs are expanding the evidence base. This review synthesizes the current research landscape, highlights emerging technologies, and discusses future directions for personalized cardiovascular care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.